Primary liver cancer
Conditions
Interventions
control group:Lipiodol + Pirubicin 50mg
experimental group:Drug-loaded microspheres + Pirubicin 50mg
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80, no gender limit; 2. Diagnosed as primary liver cancer by histopathology or clinically (refer to the Primary Liver Cancer Diagnosis and Treatment Specifications (2019 Edition)'' issued by the Ministry of Health of China); 3. Patients with liver cancer who are clinically diagnosed as unresectable liver cancer, or who are unable or unwilling to undergo surgical resection due to other reasons (such as advanced age, severe liver cirrhosis, etc.), and those who plan to undergo hepatic artery chemoembolization; 4. Patients with primary liver cancer who have not received any tumor-specific treatment for the first diagnosis and treatment; 5. Liver function Chid-Pugh classification is A or B; 6. ECOG physical fitness score = 3.0 x 10^9/L, hemoglobin >= 8.5g/dl, platelet count >= 50 x 10^9/L; INR <= 2.3 or prolonged PT <= 3 seconds, serum creatinine < 1.5 times the upper limit of normal; 8. The patient voluntarily joined the study and signed an informed consent form (ICF); 9. Those who are expected to have good compliance can follow up the efficacy and adverse reactions as required by the plan.
Exclusion criteria
Exclusion criteria: 1. There are obvious contraindications for interventional therapy: such as obvious arteriovenous fistula; uncorrectable blood coagulation dysfunction and obvious abnormal blood picture, with obvious bleeding tendency; intractable massive ascites; 2. Combined with active infection, especially inflammation of the biliary system; 3. There is a tumor thrombus in the main portal vein, or the blockage of the portal vein has more collateral vessels to compensate; 4. Severe heart, lung, kidney, brain and other important organ diseases; 5. Those who have suffered or are currently complicated by other malignant tumors (except for cured basal or squamous cell skin cancer); 6. History of allergy to iodine, chemotherapy or other related drugs; 7. Patients with poor general condition or cachexia, and the estimated survival time is short. 8. Pregnant or lactating women; 9. Other patients deemed unsuitable by the treating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tumour mutation burden (TMB);DCR;ORR; | — |
Countries
China
Contacts
Public ContactXiangyang Sun
Qilu Hospital of Shandong University
Outcome results
None listed